9. Baselga J, Albanell J, Molina MA, Arribas J (2001) Mechanism of action of trastuzumab and scientific update. Semin Oncol 28: 4–11. 10. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, et al. (1999) Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 26: 60–70. 11. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, et al. (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117–127. 12. Lee S, Yang W, Lan KH, Sellappan S, Klos K, et al. (2002) Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2- overexpressing breast cancer cells. Cancer Res 62: 5703–5710. 13. Henson ES, Hu X, Gibson SB (2006) Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression. Clin Cancer Res 12: 845–853. 14. Brandlein S, Lorenz J, Ruoff N, Hensel F, Beyer I, et al. (2002) Human monoclonal IgM antibodies with apoptotic activity isolated from cancer patients. Hum Antibodies 11: 107–119. 15. Brandlein S, Pohle T, Ruoff N, Wozniak E, Muller-Hermelink HK, et al. (2003) Natural IgM antibodies and immunosurveillance mechanisms against epithelial cancer cells in humans. Cancer Res 63: 7995–8005. 16. Imai M, Landen C, Ohta R, Cheung NK, Tomlinson S (2005) Complement- mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer. Cancer Res 65: 10562–10568. 17. Belsches-Jablonski AP, Biscardi JS, Peavy DR, Tice DA, Romney DA, et al. (2001) Src family kinases and HER2 interactions in human breast cancer cell growth and survival. Oncogene 20: 1465–1475. 18. Valabrega G, Montemurro F, Aglietta M (2007) Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 18: 977–984. 19. Huang X, Gao L, Wang S, McManaman JL, Thor AD, et al. (2010) Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin- like growth factor-i receptor in breast cancer cells resistant to herceptin. Cancer Res 70: 1204–1214. 20. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, et al. (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353: 1659–1672. 21. Green DR (1998) Apoptotic pathways: the roads to ruin. Cell 94: 695–698. 22. Green DR, Reed JC (1998) Mitochondria and apoptosis. Science 281: 1309–1312. 23. Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, et al. (2002) Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. J Clin Oncol 20: 3262–3269. 24. Galluzzi L, Kroemer G (2008) Necroptosis: a specialized pathway of programmed necrosis. Cell 135: 1161–1163. Herceptin Conjugate Induces Tumor Cell Necrosis 25. Okada N, Yin S, Asai S, Kimbara N, Dohi N, et al. (2005) Human IgM monoclonal antibodies reactive with HIV-1-infected cells generated using a trans-chromosome mouse. Microbiol Immunol 49: 447–459. 26. Ishigami T, Kim KM, Horiguchi Y, Higaki Y, Hata D, et al. (1992) Anti-IgM antibody-induced cell death in a human B lymphoma cell line, B104, represents a novel programmed cell death. J Immunol 148: 360–368. 27. Nahta R, Esteva FJ (2006) HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res 8: 215. 28. Kumar R (2007) ErbB-dependent signaling as a determinant of trastuzumab resistance. Clin Cancer Res 13: 4657–4659. 29. Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, et al. (2007) Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 13: 4909–4919. 30. Anido J, Scaltriti M, Bech Serra JJ, Santiago Josefat B, Todo FR, et al. (2006) Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO J 25: 3234–3244. 31. Scaltriti M, Rojo F, Ocana A, Anido J, Guzman M, et al. (2007) Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 99: 628–638. 32. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, et al. (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12: 395–402. 33. Pandolfi PP (2004) Breast cancer–loss of PTEN predicts resistance to treatment. N Engl J Med 351: 2337–2338. 34. Larson RA, Sievers EL, Stadtmauer EA, Lowenberg B, Estey EH, et al. (2005) Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 104: 1442–1452. 35. Amadori S, Suciu S, Stasi R, Willemze R, Mandelli F, et al. (2005) Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell’Adulto Leukemia Groups. Leuke- mia 19: 1768–1773. 36. Ghetie MA, Bright H, Vitetta ES (2001) Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood 97: 1392–1398. 37. Wolff EA, Schreiber GJ, Cosand WL, Raff HV (1993) Monoclonal antibody homodimers: enhanced antitumor activity in nude mice. Cancer Res 53: 2560–2565. 38. Hughes DP, Thomas DG, Giordano TJ, Baker LH, McDonagh KT (2004) Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res 64: 2047–2053. PLoS ONE | www.plosone.org 11 August 2011 | Volume 6 | Issue 8 | e23270